Submitted by isabela.moljf@hotmail.com (isabela.moljf@hotmail.com) on 2017-05-19T13:37:35Z No. of bitstreams: 1 luizgustavodeoliveira.pdf: 3109049 bytes, checksum: 4df3b04529f2b0980313cfda47b84ab7 (MD5) / Approved for entry into archive by Adriana Oliveira (adriana.oliveira@ufjf.edu.br) on 2017-05-19T14:46:00Z (GMT) No. of bitstreams: 1 luizgustavodeoliveira.pdf: 3109049 bytes, checksum: 4df3b04529f2b0980313cfda47b84ab7 (MD5) / Made available in DSpace on 2017-05-19T14:46:00Z (GMT). No. of bitstreams: 1 luizgustavodeoliveira.pdf: 3109049 bytes, checksum: 4df3b04529f2b0980313cfda47b84ab7 (MD5) Previous issue date: 2013-03-22 / Doenças inflamatórias intestinais, entre elas colite ulcerativa e doença de Crohn, compreendem um amplo espectro de afecções que apresentam em comum inflamação crônica do trato gastrointestinal. Colite ulcerativa afeta exclusivamente o cólon e o reto, possui etiologia ainda pouco conhecida podendo estar relacionada com fatores ambientais, genéticos e de resposta imune. O tratamento se baseia em medicamentos como aminossalicilatos, glicocorticóides e imunossupressores, porém seus efeitos colaterais atrapalham a adesão do paciente ao tratamento por longos períodos. Condroitim sulfato (CS) e glucosamina (GlcN) são atualmente indicados para o tratamento de doenças inflamatórias, como a osteoartrite, principalmente por apresentarem efeito anti-inflamatório ao diminuírem a ação do fator de transcrição NF-kB diminuindo a expressão de metaloproteases (MMP), TNF-α, iNOS entre outros mediadores inflamatórios. O objetivo deste trabalho foi analisar os efeitos da associação de CS e GlcN na colite ulcerativa experimental induzida por dextran sulfato de sódio (DSS) em ratos Wistar. Para isso foram avaliados o índice de atividade da doença (IAD), parâmetros hematológicos e bioquímicos, morfológicos e a atividade de MMP-2 e -9 da matriz extracelular no intestino grosso, concentração de NO tecidual e concentração de glicosaminoglicanos. Os animais foram divididos em quatro grupos: (1) controle, (2) controle + CS/GlcN, (3) DSS , (4) DSS + CS/GlcN. Observamos que o tratamento com CS/GlcN melhorou a severidade da colite aguda em ratos, verificado pela redução do score histológico e melhora de parâmetros hematológicos. CS/GlcN também reduziu a destruição de células caliciformes observados pelo azul de alcian, bem como a produção de óxido nítrico, a atividade de mieloperoxidase e metaloproteases, principalmente de MMP-9. Além disso, foi observado uma redução na concentração de GAGs total no grupo DSS + CS/GlcN quando comparado ao grupo DSS. Portanto, a administração de CS/GlcN apresentou melhoras em alguns dos parâmetros avaliados principalmente na atividade de MMP-9, mostrando um potencial destes compostos para futura utilização no tratamento dessa patologia. / Inflammatory bowel disease, including ulcerative colitis and Crohn's disease comprising a broad spectrum of diseases those have in common chronic inflammation of the gastrointestinal tract. Ulcerative colitis affects only the colon and rectum, has still poorly understood etiology and this could may be related to environmental factors, genetic and immune response. Treatment is based on drugs as aminosalicylates, immunosuppressants and glucocorticoids, but its side effects hinder patient compliance with treatment for long periods. Chondroitin sulphate (CS) and glucosamine (GlcN) are currently indicated for treatment of inflammatory diseases such as osteoarthritis, mainly because of the anti-inflammatory effect by decreasing the activity of transcription factor NF-kB and decreasing the expression of metalloproteases (MMP), TNF-α, iNOS and other inflammatory mediators. The objective of this study was to analyze the effects of the combination of CS and GlcN in experimental ulcerative colitis model induced by dextran sulfate sodium (DSS) in rats. To do so we evaluated the disease activity index (DAI), haematological and biochemical parameters, morphological changes and activity of MMP-2 and -9, NO and glycosaminoglycans concentration in the large intestine. Animals were divided into four groups: (1) control, (2) control + CS / GlcN, (3) DSS-induced colitis, (4) DSS + CS / GlcN. We observed that treatment with CS/GlcN improved the severity of acute colitis in rats verified by histological score reduction and improvement in hematological parameters. CS/GlcN also reduced goblet cells destruction observed by alcian blue, as well as nitric oxide production, the activity of myeloperoxidase and metalloproteases, especially MMP-9. Moreover, we observed a reduction in the concentration of total GAG + DSS group CS / GlcN when compared to DSS. Therefore, administration of CS/GlcN showed improvements in some of the parameters evaluated mainly on the activity of MMP-9, showing a potential future use of these compounds for the treatment of this pathology.

Les maladies cardiovasculaires continuent à être parmi les principales sources de morbidité et de mortalité dans le monde [1, 2]. Malgré les avancées importantes dans le traitement médical et endovasculaire de ces pathologies, le besoin en revascularisations artérielles par pontage ne cesse de prendre de l’ampleur. Les conduits vasculaires synthétiques actuels performent bien lorsqu’utilisés pour des vaisseaux de calibre moyen, mais ceux de petit diamètre (< 6 mm) démontrent encore à ce jour des taux de perméabilité beaucoup trop bas [3-11]. Deux hypothèses pouvant expliquer ce phénomène sont le manque d’endothélialisation et de compliance des conduits synthétiques actuels [12-18]. Le but de cette étude était de créer et d’évaluer la performance d’un nouveau conduit de petit diamètre avec un potentiel d’endothélialisation supérieur et une compliance similaire aux vaisseaux natifs. Cette étude présente deux aspects distincts : l’élaboration et l’évaluation in vitro d’un conduit électrofilé de petit diamètre (5 mm) composé d’une structure de polyuréthane/polycaprolactone (PU/PCL) et d’un revêtement bioactif de sulfate de chondroïtine (CS) par une équipe spécialisée en biomatériaux, puis l’élaboration et l’évaluation d’un essai in vivo mettant à l’épreuve la performance du néo-conduit dans un modèle de grand animal par une seconde équipe. Les conduits à l’étude (eVG-CS) ont démontré une compliance 10 fois supérieure à celle des conduits de polytétrafluoroéthylène expansé (ePTFE) actuellement utilisés en clinique, ainsi qu’une bonne stabilité au vieillissement in vitro. L’évaluation in vivo, sous forme de pontages carotidiens bilatéraux chez le mouton, a par contre démontré l’infériorité des conduits à l’étude comparativement aux contrôles en ePTFE en termes de perméabilité et de par l’absence d’endothélialisation significative des greffons à l’étude. L’infériorité in vivo de ces nouveaux pontage électrofilés bioactifs par rapport aux résultats favorables in vitro fut attribuée principalement à la trop faible porosité des greffons à l’étude ainsi qu’à l’incapacité du revêtement de CS à favoriser un processus d’endothélialisation rapide. L’établissement d’un greffon plus poreux avec un revêtement bioactif différent représente une piste d’amélioration future de cette structure prometteuse de PU/PCL. / Cardiovascular diseases present a growing burden of morbidity and mortality worldwide [1, 2]. Despite significant advances in medical and endovascular treatments of these pathologies, the need of revascularization by arterial bypass is increasing. Actual synthetic vascular conduits perform well when used on large-diameter arteries, but small-diameter conduits (<6 mm) still show unacceptably low medium- and long-term permeability rates [3-11]. Two hypotheses can explain this phenomenon – the inability of synthetic bypasses to create a neo-endothelium and compliance mismatch between the graft and the native artery [12-18]. The goal of this study was to create and evaluate the performance of a novel small-diameter vascular conduit with superior endothelialization properties and a compliance similar to native vessels. This study presents two distinct aspects : the in vitro elaboration and evaluation of an electrospun, small-diameter (5 mm) vascular conduit made up of a scaffold of polyurethane/polycaprolactone (PU/PCL) combined with a chondroitin sulfate (CS) bioactive coating by a team specialized in biomaterials, and the elaboration and evaluation of an in vivo trial testing the performance of the novel vascular graft in a large animal model by a second team. The experimental conduits (eVG-CS) showed an in vitro compliance 10-times superior to their commercially-available expanded polytetrafluoroethylene (ePTFE) counterparts, while remaining stable after aging trials. However, in vivo evaluation, as bilateral interposition carotid bypasses in sheep, showed the novel bypasses to be inferior to ePTFE controls in terms of permeability and by the absence of significant endothelialization. The in vivo inferiority of these novel bioactive electrospun grafts despite favorable in vitro results was attributed to the low porosity of the grafts and to the inability of the CS coating to promote the endothelialization process. Establishment of a more porous graft with a different bioactive coating represents the future of the evaluation of this promising PU/PCL structure.

Ce travail est consacré à l'élaboration de nano-complexes polyélectrolytes (CPEs) ayant une stabilité améliorée en milieux physiologiques et à l'exemplification de leur fort potentiel d'application comme système de délivrance de (macro) molécules bioactives. Le chitosane comme polycation a été compléxé avec quatre polyanions naturels ayant différents densités de charges et groupements fonctionnels(-COO- et SO3-) à savoir l'acide hyaluronique (HYA), le chondroïtine sulfate (ChonS), le sulfate de dextrane (DS) et l'héparine (HEP). Les facteurs qui influent sur la formation et les propriétés physico-chimiques des nano-complexes chitosane-HYA ont été étudiés. Ces nanovecteurs perdent leur caractère colloïdal en milieux physiologiques. Pour améliorer leur stabilité dans ces conditions, une stratégie innovante qui implique l'ajout de zinc a été conçue. Cette stratégie de stabilisation a été démontrée comme étant polyvalente et a été étendue aux complexes polyélectrolytes (CPEs) chitosane-ChonS. Même si de cette manière une stabilité à long terme a été observée, cette stratégie reste uniquement applicable aux CPEs cationiques. Pour cette raison, une approche alternative permettant l'amélioration de la stabilité des colloïdes à charges positives ou négatives a été mise en oeuvre en concevant des nano-complexes de type coeur-couronne ternaires composés de polyacides forts c'est-à-dire de DS ou d'HEP associés au chitosane en coeur et un complexe chitosane-HYA en couronne. Tous les nano-complexes stables obtenus peuvent encapsuler le ténofovir, une molécule antirétrovirale et être fonctionnalisés par des IgAs de ciblage. En in vitro, ces nanovecteurs montrent une inhibition de l'infection des PBMC par le virus VIH-1 supérieure à l'antirétrovirale seule / This work is devoted to the elaboration of nano-polyelectrolyte complexes (PECs) systems with improved stability in physiological media and to the establishment of their high potential of applications as bioactive (macro) molecule delivery systems. Chitosan as polycation were complexed with four natural polyanions of different charged groups and densities (-COO- and SO3 - as negative charges), namely hyaluronan (HYA), chondroitin sulfate (ChonS), dextran sulfate (DS) and heparin (HEP). The factors impacting the formation and physical-chemical properties of chitosan-HYA nanocomplexes were investigated. However, these nanovectors lost their colloidal character in physiological media. To improve their colloidal stability in physiological conditions, an innovative stabilization strategy was designed, involving zinc ion. This stabilization strategy proved versatile and was extended to chitosan-ChonS PECs. Though a long-term stability was achieved, this strategy was only applicable to cationic PECs. Therefore, an alternate approach enabled the improvement of the colloidal stability in physiological media of both positive and negative colloids by designing core-shell ternary polyelectrolyte nanocomplexes composed of strong polyacid (DS or HEP)-chitosan PECs as core and a chitosan-HYA complex as shell. Furthermore, all of the stabilized nanocomplexes allowed the encapsulation of active molecules anti-retroviral drug tenofovir and surface functionalization with targeting IgAs. In vitro, these nanovectors exhibited an inhibition of infection of PBMCs by HIV-1 virus which could be superior to the free drug

Skeletal muscle injuries and muscle degenerative diseases pose significant challenges to the healthcare. Surgical interventions are restricted due to tissue availability, donor site morbidity and alterations to tissue biomechanics. Current cell-based therapies are hindered by low survival and long-term engraftment for the transplanted cells due to the lack of appropriate supportive microenvironment (cell niche) in the injured muscle. Therefore, there is a critical need for developing strategies that provide cellular and structural support in the regeneration of functional muscle. In the present work, a bioengineered cell niche mimicking the native skeletal muscle microenvironment has been developed for skeletal muscle regenerative engineering. It is hypothesized that the bioengineered scaffolds with appropriate structural and cell instructive properties will support myoblast alignment and function, as well as promote the myogenic responses in clinically relevant skeletal muscle injuries. The current work utilized a three-pronged approach to design biomaterial scaffolds to aid in skeletal muscle regeneration. In the first part, aligned poly(lactide-co-glycolide) (PLGA) fiber scaffolds mimicking the oriented muscle fiber microenvironment with fiber diameters of 335±154 nm (nanoscale), 1352±225 nm (microscale) and 3013±531 nm (microscale) were fabricated and characterized. Myoblasts were found to respond to fiber diameter as observed from the differences in cell alignment, cell elongation, cell spreading area, proliferation and differentiation. <i>In vivo</i> study demonstrated the potential of using microscale fiber scaffolds to improve myogenic potential in the <i>mdx</i> mouse model. In the second part, we designed, synthesized, and characterized an implantable glycosaminoglycan-based composite hydrogel consisting of hyaluronic acid, chondroitin sulfate and polyethylene glycol (HA-CS) with tailored structural and mechanical properties for skeletal muscle regeneration applications. We demonstrated that HA-CS hydrogels provided a suitable microenvironment for <i>in vitro</i> myoblast proliferation and differentiation. Furthermore, <i>in vivo</i> studies using a volumetric muscle loss model in the mouse quadriceps showed that HA-CS hydrogels integrated with the surrounding host tissue and facilitated <i>de novo</i> myofiber generation, angiogenesis, nerve innervation and minimized scar tissue formation. In the third part, we investigated the effects of PC12 secreted signaling factors in modulating C2C12 myoblast behavior. We showed that PC12 conditioned media modulated myoblast proliferation and differentiation in both 2D culture and 3D aligned electrospun fiber scaffold system in a dose dependent manner. We also demonstrated the biomimetic HA-CS hydrogel system enabled 3D encapsulation of PC12 cells secreting signaling factors and promoted survival and proliferation of myoblasts in co-culture. Further proteomics analysis identified a total of 2088 protein/peptides from the secretome of the encapsulated PC12 cells and revealed the biological role and overlapping functions of nerve secreted proteins for skeletal muscle regeneration, potentially through regulating myoblast behavior, nerve function, and angiogenesis. These set of experiments not only provide critical insight on exploiting the interactions between muscle cells and their microenvironment, but they also open new avenues for developing advanced bioengineered scaffolds for regenerative engineering of skeletal muscle tissues.<br>

No description available.

La réparation endovasculaire (EVAR) est une technique minimalement invasive permettant de traiter l’anévrisme de l’aorte abdominale (AAA) par l’entremise d’un stent- graft (SG). L’utilisation d’EVAR est actuellement limitée par de fréquentes complications liées à une guérison inadéquate autour de l’implant. Ce manque de guérison est principalement dû au type de recouvrement polymérique des SG, au milieu pro-apoptotique des AAA et à l’accès réduit aux nutriments et à l’oxygène après EVAR. L’objectif de cette thèse consistait à concevoir un revêtement bioactif permettant d’inhiber l’apoptose et stimuler la croissance des cellules musculaires lisses vasculaires (CMLV), pour ainsi favoriser la guérison des tissus vasculaires autour des SG. La chondroïtine-4-sulfate (CS) a d’abord été choisie, car elle a été identifiée comme un médiateur important de la réparation vasculaire. Il a été démontré que la CS en solution influence directement la résistance à l’apoptose des CMLV, en plus de favoriser la différenciation myofibroblastique chez les fibroblastes. Dans le cadre de ce projet, un premier revêtement à base de CS et de collagène a été créé. Bien que le revêtement permettait d’induire une résistance à l’apoptose chez les CMLV, il se désintégrait trop rapidement dans des conditions aqueuses. Une nouvelle méthodologie a donc été adaptée afin de greffer la CS directement sur des surfaces aminées, à l’aide d’un système utilisant un carbodiimide. Dans le but d’accroître la croissance des CMLV à la surface des revêtements, le facteur de croissance de l’épiderme (EGF) a ensuite été sélectionné. En plus de ses propriétés mitogéniques et chimiotactiques, l’EGF stimule la production d’éléments de la matrice extracellulaire, comme le collagène et la fibronectine. De plus, l’activation du récepteur de l’EGF inhibe également l’apoptose des CMLV. L’EGF a donc été greffé sur la CS. Le revêtement de CS+EGF a démontré une bonne uniformité et bioactivité sur des surfaces de verre aminé. iii iv Dans une 3ème étape, afin de permettre de transposer ce revêtement bioactif sur des implants, plusieurs méthodes permettant de créer des groupements d’amines primaires sur les biomatériaux polymériques comme le PET ou le ePTFE ont été étudiées. La polymérisation par plasma a été choisie pour créer le revêtement CS+EGF à la surface de PET. Une fois de plus, celui-ci a permis d’inhiber l’apoptose des CMLV, dans des conditions pro-apoptotiques, et de favoriser la croissance des cellules. Le revêtement de CS et d’EGF, déposé sur des surfaces aminées, possède des caractéristiques biologiques intéressantes et semble donc prometteur pour favoriser une meilleure guérison autour des SG. / Endovascular aneurysm repair (EVAR) is a minimally invasive technique performed to treat abdominal aortic aneurysm (AAA) through the use of a stent-graft (SG). The usage of EVAR is presently limited by postoperative complications related to an incomplete healing of the surrounding tissues. The materials currently used in SG, the pro- apoptotic phathophysiology of AAA and the limited access to nutrients and oxygen, all limit the wound healing process and proper tissue ingrowth around the implant. The main objective of this thesis was to create of a bioactive coating inhibiting cell apoptosis and increasing vascular smooth muscle cells (VSMC) growth, to promote healing of the vascular tissues surrounding SG. Chondroitin sulfate (CS) was chosen since recent findings have shown that this polysaccharide triggers key mechanisms involved in vascular repair. CS in solution was shown to inhibit apoptosis of VSMC, as well as stimulate myofibroblast differentiation. A coating of CS and collagen was first created for the purpose of this work. Although the coating was shown to increase cell resistance to apoptosis with VSMC, it was not stable enough, since it rapidly disintegrated in aqueous solutions. A new methodology was thus proposed, where CS was grafted right on aminated surfaces, through carbodiimide chemistry. Epidermal growth factor (EGF) was then chosen to increase VSMC growth on the coatings. EGF is a known mitogenic and chemotactif growth factor for VSMC. It also stimulates the production of extracellular matrix elements, such as collagen and fibronectin. The activation of EGF receptor (EGFR) also triggers various cell signalling pathways modulating VSMC resistance to apoptosis. EGF was thus grafted on CS. CS+EGF coating on aminated glassed slides was shown to be uniform and bioactive. Finally, several methodologies to produce primary amines on polymeric biomaterials, such as PET and ePTFE, were studied in order to eventually transfer the v vi coating on implants. Plasma polymerization was chosen to create the CS+EGF coating. Once again the coating was shown to decrease VSMC apoptosis, in apoptotic conditions, and favour cell growth. Overall, the CS and EGF coating on aminated surfaces possesses interesting biological features and is a promising avenue to stimulate vascular healing around SG.

En janvier 2008, une éclosion de réactions anaphylactoïdes (RA) potentiellement mortelles associées à l’injection intraveineuse d’héparine manufacturées en Chine et contaminée par le chondroïtine sulfate hypersulfaté (CSHS) a forcé le rappel de ces dernières par la U.S. Food and Drug Administration. Ces RA ont rapidement été attribuées à la libération de la bradykinine (BK) suite à l’activation du système de contact par le CSHS. Cependant, aucune évidence expérimentale définitive n’est à ce jour venue appuyer directement cette hypothèse. En se basant sur le nombre de morts déclaré et associé à la contamination (>150 morts au niveau mondial) ainsi qu’aux données épidémiologiques, qui stipulent que 25% des patients ayant développés une RA aux États-Unis étaient essentiellement des insuffisant rénaux en dialyse traités au moyen d’un inhibiteur de l’enzyme de conversion de l’angiotensine (iECA), nous avons émis l’hypothèse suivante : les RA causées par l’injection intraveineuse d’héparine contaminée au CSHS sont de nature multifactorielle et complexe. Le but de notre travail est donc, dans un premier temps, d’évaluer le pouvoir kininoformateur du CSHS en présence d’un iECA et de le comparer à celui du sulfate de dextran, un activateur de référence du système de contact. Comme les RA associées à l’injection intraveineuse d’héparine contaminée par le CSHS se produisent généralement dans les premières minutes des séances de dialyse, nous allons étudier l’effet de la dilution du plasma sur la quantité de BK libérée en présence ou en absence d’un iECA. Nous allons également mesurer les profils cinétiques de la libération de la BK sur un plasma stimulé par différents lots d’héparine contaminée, et associée à des RA, et nous comparerons cette cinétique avec celles d’une héparine de référence complémentée ou non avec différentes concentrations de CSHS synthétique. Enfin, nous allons caractériser le profil de libération de la BK et de son métabolite actif, la des-Arg9-BK, dans le plasma de patients dialysé ayant présenté une RA associée à une membrane de dialyse chargée négativement. L’application de méthodes expérimentales développées dans notre laboratoire nous a permis de montrer, pour la première fois, que l’héparine contaminée au CSHS a la capacité de libérer la BK à des concentrations susceptibles d’expliquer le rôle de ce peptide inflammatoire dans la physiopathologie des RA causées par l’injection intraveineuse d’héparine d’origine chinoise contaminée au CSHS. / In January 2008, fatal anaphylactoid reaction (AR) has been associated to oversulfated chondroitin sulphate (OSCS) contaminated heparin. Although attributed to bradykinin (BK) released during contact system activation by OSCS, no definitive evidence exists until now for a BK release during incubation of contaminated heparin with human plasma. While looking at the number of death associated with OSCS (>150 worldwide) and at the epidemiologic fact, who state that 25% of the cases of AR associated to OSCS in United-States were treated with an angiotensin converting enzyme inhibitor (ACEi), we hypothesis that: AR associated with bolus injection of OSCS contaminated heparin are bind to a complex and multi-factorial aspect. The first objective of our study is to measure the kinetics of BK release in human plasma incubated with OSCS in presence of an ACEi and to compare it to the kinetics profile of the reference activator dextran sulfate. As the AR associated with OSCS contaminated heparin occurred mainly in the first minutes of dialysis session, we also studied the effect of the plasma dilution on the amount of BK released when treated or not with an ACEi. We also quantify the BK forming capacity of different batches of OSCS contaminated heparin responsible for AR and we compare this effect with reference heparin spiked or not with increasing concentrations of synthetic OSCS. Finally, we measure the kinetics of BK and des- Arg9-BK, its active metabolite, release in human plasma collected from patients who developed an AR associated to negatively charged dialysis membrane. The application of experimental method developed in our laboratory show, for the first time, that OSCS contaminated heparin incubated with human plasma has the capacity to liberate BK at a concentration that could explain the role of this inflammatory peptide in the pathophysiology of AR associated with OSCS contaminated Chinese heparins.

Racional: A epilepsia do lobo temporal está comumente associada à farmacorresistência e tem a esclerose hipocampal como achado neuropatológico em mais da metade dos casos. Histologicamente, a esclerose hipocampal está associada à perda neuronal diferencial e gliose, além de alterações nos níveis de moléculas associadas à homeostase da água tecidual, como a aquaporina 4 e a molécula de matriz sulfato de condroitina. Em imagens de ressonância nuclear magnética, a esclerose é caracterizada por redução de volume em sequências ponderadas em T1, aumento de sinal e tempo de relaxamento em sequências ponderadas em T2 e redução na transferência de magnetização. Justificativa e Objetivos: Uma vez que tanto o sinal T2 quando a transferência de magnetização são dependentes da água tecidual, nosso objetivo é avaliar, na formação hipocampal de pacientes com epilepsia do lobo temporal, as correlações entre populações celulares e moléculas ligadas à homeostase da água e as imagens ponderadas em T2 e transferência de magnetização. Visamos ainda definir, na formação hipocampal de indivíduos sem alterações neuropatológicas, o volume de cada um dos subcampos hipocampais. Metodologia: Pacientes com epilepsia do lobo temporal farmacorresistente (ELT, n = 43), bem como voluntários sadios (controle radiológico, CH, n = 20), foram submetidos a exames de ressonância magnética em máquina de 3T para mensuração da volumetria hipocampal, tempo de relaxamento T2 e transferência de magnetização hipocampal (exames in vivo). Após o tratamento cirúrgico para o controle das crises, os hipocampos dos pacientes com ELT foram fixados por 8 dias e submetidos aos exames ex vivo em máquina de 3T para cálculo do tempo de relaxamento T2 de cada subcampo hipocampal. Hipocampos controle (Controle historadiológico, CHR, n = 14), foram obtidos de autópsias de pacientes sem histórico ante-mortem de doença neurológica ou presença de patologia no exame do encéfalo pos mortem. Ambos os grupos controle foram pareados para idade em relação ao grupo ELT. Alguns dos casos CHR (n = 6) foram também submetidos à imagem 3D T2 em máquina de 4,7T para cálculo de volumetria dos subcampos hipocampais. Após emblocamento em parafina, secções coronais hipocampais dos casos CHR e ELT foram submetidas às técnicas de histoquímica básica Hematoxilina e Eosina e Luxol Fast Blue, e às imuno-histoquímicas para avaliação das populações neuronais (NeuN), astrócitos reativos (GFAP), micróglias ativadas (HLA-DR) e para a expressão de aquaporina 4 (AQP4) e níveis de sulfato de condroitina (CS-56). Para a comparação entre os grupos, foram realizados testes t para dados paramétricos e Mann-Whitney para dados não-paramétricos. Testes de correlação foram empregados para análise da associação entre as avaliações histológicas e os exames de ressonância magnética. Resultados: Pacientes com ELT apresentaram menor volume hipocampal, maior tempo de relaxamento T2 e menor transferência de magnetização no exame in vivo, quando comparados com o CR. O exame ex vivo para a volumetria dos subcampos hipocampais em casos do grupo CHR indicou que a fascia dentata, a região CA1 e o subículo correspondem à 85 % do volume hipocampal total. Quanto ao tempo de relaxamento T2 ex vivo, foi observado aumento em todos os subcampos hipocampais do grupo ELT, à exceção da fascia dentata, quando comparados ao CHR. A avaliação da densidade neuronal indicou redução significativa em todos os subcampos dos casos ELT, à exceção do subículo, quando comparados ao CHR. Em relação aos valores do grupo CHR, foi observada astrogliose em quase todos subcampos da formação hipocampal (a exceção da zona subgranular e do hilo) e microgliose em todos os subcampos (exceto pelo subículo) dos casos com ELT. Pacientes com ELT apresentaram redução na expressão de aquaporina 4 perivascular em todos os subcampos do hipocampo, comparados ao CHR. Aumento nos níveis de sulfato de condroitina foi observado em todos os subcampos da formação hipocampal, à exceção da camada granular, nos pacientes com ELT. O volume hipocampal e a transferência de magnetização in vivo dos pacientes com ELT correlacionaram-se tanto com a população neuronal como com os níveis de sulfato de condroitina, enquanto que o tempo de relaxamento in vivo correlacionou-se com a população astroglial e os níveis de sulfato de condroitina. O exame ex vivo corroborou a correlação entre a população glial e o tempo de relaxamento observado nos pacientes com ELT. A diferença entre o tempo de relaxamento in vivo e ex vivo correlacionou-se tanto com a difusibilidade da água no tecido como com os níveis de sulfato de condroitina. Conclusões: Nossos dados indicam correlação entre a patologia hipocampal e as imagens de ressonância nuclear magnética, sendo que a maior qualidade das imagens ex vivo permitiu uma avaliação mais direta entre o sinal de ressonância e a patologia, indicando importância da população celular e matriz extracelular para o volume hipocampal e a transferência de magnetização, e da astrogliose para o tempo de relaxamento T2. Finalmente, nossos dados mostraram que CA1, subículo e fascia dentata tem grande participação no volume hipocampal, sendo que alterações nestas regiões tem um papel mais relevante nas alterações observadas na ressonância magnética, como indicado por nossas correlações. / Rationale: Drug resistant temporal lobe epilepsy is often associated with hippocampal sclerosis. Histological evaluation reveals differential neuronal loss, gliosis and changes in molecules associated with water homeostasis, such as aquaporin 4 and chondroitin sulfate. Magnetic resonance imaging in these cases often reveals hippocampal atrophy, increased T2 signal and T2 relaxation and reduced magnetization transfer ratio in the hippocampus. Aims: Once both T2 signal and magnetization transfer are affected by tissue water, our goal was to evaluate, in the hippocampus of drug-resistant temporal lobe epilepsy patients who underwent surgery for seizure control, the associations between cellular populations, aquaporin 4 and chondroitin sulfate with T2 relaxation time and magnetization transfer. Additionally, we intended to measure the individual volume of each hippocampal subfield in hippocampus from patients without neurological disease. Methods: Patients with drug-resistant temporal lobe epilepsy (TLE, n = 43) and age-matched health volunteers (radiological control, RC, n = 20) were submitted to magnetic resonance in a 3T machine for hippocampal volumetry measure, T2 relaxation and magnetization transfer (in vivo examination). After surgical treatment for seizure control, hippocampi from the TLE patients were fixed in formalin for 8 days and then submitted to ex vivo imaging in 3T for relaxation time of every hippocampal subfield. Control hippocampi were obtained from autopsies of age-matched patients without ante mortem history of neurological disease or post mortem neurological pathology, and underwent the same ex vivo imaging (histo-radiological control, HRC, n = 14). Six cases from the HRC underwent 3D T2 imaging in a 4.7T machine, in order to measure the volumes of the hippocampal subfields. Paraffin embedded hippocampal sections from TLE and HRC were submitted to Hematoxilin-Eosin and Luxol Fast Blue histochemistries, and to immunohistochemistries for the evaluation of neurons (NeuN), reactive astrocytes (GFAP), activated microglia (HLA-DR), for aquaporin 4 (AQP4) and for chondroitin sulfate (CS-56). Students t-test or Mann-Whitneys test were performed for comparison between groups, and correlation tests were performed for the comparison between histological and magnetic resonance measures. Results: Patients with TLE presented reduced hippocampal volume, increased T2 relaxation time and reduced magnetization transfer, when compared to RC. The ex vivo volumetry of the hippocampal subfields revealed that fascia dentata, CA1 and subiculum together correspond to 85 % of the total hippocampal volume. Ex vivo relaxation time, as the in vivo, were increased in the subfields of TLE patients, when compared to HRC. Compared to HRC, TLE patients presented neuron loss and microgliosis in all hippocampal subfields but the subiculum, and astrogliosis in all hippocampal subfields but the subgranule zone and the hilus. Reduced perivascular aquaporin 4 was observed in all hippocampal subfields of TLE patients, and increased chondroitin sulfate was observed in all hippocampal subfields, with the exception of granule cell layer, of TLE patients, when compared to HRC. In TLE, both in vivo hippocampal volume and magnetization transfer correlated with the levels of chondroitin sulfate and the neuronal population, whereas the in vivo relaxation time correlated with the astroglial population and the levels of chondroitin sulfate. Ex vivo relaxation time also correlated with the astroglial population in TLE patients. The difference between in vivo and ex vivo relaxation values correlated with water difusibility and the levels of chondroitin sulfate. Conclusion: Our data indicate the importance of neuron population and extracellular matrix to both hippocampal volume and magnetization transfer, and of the reactive astrocytes for T2 relaxation. Ex vivo relaxation time allowed a more detailed evaluation, and indicated more robust correlations between reactive astrocytes and T2 relaxation. Finally, Our data indicated that CA1, the subiculum and fascia dentata are the major contributors to hippocampal volume, so changes in these subfields most likely will affect magnetic resonance imaging.

OBJETIVOS: Avaliar o efeito de sulfato de glicosamina e sulfato de condroitina sobre a nocicepção e o dano da cartilagem articular em um modelo de osteoartrite experimental em ratos. MÉTODOS: Osteoartrite (OA) foi induzida em ratos Wistar machos por transecção do ligamento cruzado anterior (TLCA) do joelho direito. Um grupo falso-operado (SHAM) foi utilizado como controle. Animais OA foram tratados v.o. desde 7 dias antes, até o sacrifício, 70 dias após a TLCA, com sulfato de glicosamina 500 mg/kg (Glu), a combinação sulfato de glicosamina 500 mg/kg e sulfato de condroitina 400 mg/kg (GluChon), ou salina (OANT). Um grupo controle positivo recebeu meloxicam 6 mg/kg s.c. A dor articular foi avaliada pelo teste de incapacitação articular para ratos. Os animais foram sacrificados em diferentes períodos (7,14,28 e 70 dias) após a TLCA. A gravidade das lesões histopatológicas foi graduada nos fêmures após coloração por H&E e azul de toluidina através do escore da OARSI. A quantidade de glicosaminoglicanos (GAGs) extraídos da cartilagem articular dos côndilos femorais foi medida após eletroforese em gel de agarose. O tamanho molecular dos GAGs foi medido após eletroforese em gel de poliacrilamida. A liberação de NO no líquido sinovial foi medida 7 dias após TLCA. RESULTADOS: GluChon reduziu significativamente a dor articular nesse modelo (p<0,01). Glu também reduziu a dor articular, mas não se alcançou significância estatística. Os animais OA apresentaram um aumento significativo dos GAGs na cartilagem articular aos 70 dias após TLCA (77,68±3,38 µg/mg) quando comparados aos animais SHAM (53,46±4,58 µg/mg). O tamanho molecular dos GAGs foi significativamente maior nos animais OA que nos animais SHAM 70 dias após a cirurgia (p<0,01). GluChon preveniu tanto o aumento da quantidade de GAGs (54,42±5,39 µg/mg), quanto de seu tamanho molecular (p<0,05), e estes resultados acompanharam-se de melhora significativa da lesão histopatológica (p<0,05). Os resultados obtidos com Glu foram semelhantes, porém menos evidentes, e não alcançaram significância estatística. Glu aumentou significativamente a quantidade de NO na cavidade articular 7 dias após a TLCA. CONCLUSÕES: GluChon foi antinociceptivo e reduziu significativamente a incapacitação articular. A lesão da cartilagem articular no modelo de TLCA em ratos se acompanha de aumento da concentração e do tamanho molecular dos GAGs, e o tratamento com GluChon previne essas alterações e reduz o dano histopatológico. GluChon foi mais eficaz do que Glu tanto na redução da dor quanto da lesão da cartilagem articular, sugerindo benefício da combinação sobre o uso isolado de sulfato de glicosamina. / OBJECTIVES: Evaluate the antinociceptive and chondroprotective effects of glucosamine sulfate and chondroitin sulfate. METHODS: Male Wistar rats underwent anterior cruciate ligament transection (ACLT) or sham operation of the right knee. Animals were treated p.o. with glucosamine sulfate (Glu) 500 mg/kg, the combination of glucosamine sulfate 500 mg/kg and chondroitin sulfate 400 mg/kg (GluChon), or saline, since 7 days prior to surgery until the sacrifice 70 days after ACLT. A positive control group received meloxicam 6 mg/kg s.c. for antinociceptive evaluation comparisons. Joint pain was evaluated with rat incapacitation test. Animals were sacrificed 7,14,28 or 70 days after ACLT. The severity of histopathologic lesions was evaluated on femoral condyles after hematoxylin-eosin or toluidine blue staining with OARSI grading and staging system. Cartilage extracted glycosaminoglycans (GAGs) concentration was assessed after agarose gel electrophoresis. GAGs\' molecular weight was evaluated after polyacrylamide gel electrophoresis. NO release in synovial fluids was assessed 7 days after ACLT. RESULTS: GluChon reduced joint pain (p<0.01). Glu also reduced joint pain, but results did not reach statistical significance. A significant increase in articular cartilage\'s GAGs concentration was observed in OA animals (77.68±3.38 µg/mg) as compared to sham (53.46±4.58 µg/mg). OA animals also had significantly higher molecular weight GAGs than sham (p<0.01). GluChon prevented both GAG concentration and molecular weight elevations in OA animals, and that was associated with significant less cartilage damage assessed by histopathologic examination (p<0.05). Glu effects were less evident, and did not reach statistical significance. Glu was associated with significant higher concentrations of NO in synovial fluid. CONCLUSIONS: GluChon was antinociceptive on the ACLT model in rats. Articular cartilage damage was associated with increased amounts of GAG with higher molecular weight, and the prevention of these alterations with GluChon treatment was associated with less histopathologic damage. GluChon was more efficient than Glu for both pain and articular cartilage damage reduction, suggesting that combined treatment is better than glucosamine sulfate alone.

OBJETIVOS: Avaliar o efeito de sulfato de glicosamina e sulfato de condroitina sobre a nocicepção e o dano da cartilagem articular em um modelo de osteoartrite experimental em ratos. MÉTODOS: Osteoartrite (OA) foi induzida em ratos Wistar machos por transecção do ligamento cruzado anterior (TLCA) do joelho direito. Um grupo falso-operado (SHAM) foi utilizado como controle. Animais OA foram tratados v.o. desde 7 dias antes, até o sacrifício, 70 dias após a TLCA, com sulfato de glicosamina 500 mg/kg (Glu), a combinação sulfato de glicosamina 500 mg/kg e sulfato de condroitina 400 mg/kg (GluChon), ou salina (OANT). Um grupo controle positivo recebeu meloxicam 6 mg/kg s.c. A dor articular foi avaliada pelo teste de incapacitação articular para ratos. Os animais foram sacrificados em diferentes períodos (7,14,28 e 70 dias) após a TLCA. A gravidade das lesões histopatológicas foi graduada nos fêmures após coloração por H&E e azul de toluidina através do escore da OARSI. A quantidade de glicosaminoglicanos (GAGs) extraídos da cartilagem articular dos côndilos femorais foi medida após eletroforese em gel de agarose. O tamanho molecular dos GAGs foi medido após eletroforese em gel de poliacrilamida. A liberação de NO no líquido sinovial foi medida 7 dias após TLCA. RESULTADOS: GluChon reduziu significativamente a dor articular nesse modelo (p<0,01). Glu também reduziu a dor articular, mas não se alcançou significância estatística. Os animais OA apresentaram um aumento significativo dos GAGs na cartilagem articular aos 70 dias após TLCA (77,68±3,38 µg/mg) quando comparados aos animais SHAM (53,46±4,58 µg/mg). O tamanho molecular dos GAGs foi significativamente maior nos animais OA que nos animais SHAM 70 dias após a cirurgia (p<0,01). GluChon preveniu tanto o aumento da quantidade de GAGs (54,42±5,39 µg/mg), quanto de seu tamanho molecular (p<0,05), e estes resultados acompanharam-se de melhora significativa da lesão histopatológica (p<0,05). Os resultados obtidos com Glu foram semelhantes, porém menos evidentes, e não alcançaram significância estatística. Glu aumentou significativamente a quantidade de NO na cavidade articular 7 dias após a TLCA. CONCLUSÕES: GluChon foi antinociceptivo e reduziu significativamente a incapacitação articular. A lesão da cartilagem articular no modelo de TLCA em ratos se acompanha de aumento da concentração e do tamanho molecular dos GAGs, e o tratamento com GluChon previne essas alterações e reduz o dano histopatológico. GluChon foi mais eficaz do que Glu tanto na redução da dor quanto da lesão da cartilagem articular, sugerindo benefício da combinação sobre o uso isolado de sulfato de glicosamina. / OBJECTIVES: Evaluate the antinociceptive and chondroprotective effects of glucosamine sulfate and chondroitin sulfate. METHODS: Male Wistar rats underwent anterior cruciate ligament transection (ACLT) or sham operation of the right knee. Animals were treated p.o. with glucosamine sulfate (Glu) 500 mg/kg, the combination of glucosamine sulfate 500 mg/kg and chondroitin sulfate 400 mg/kg (GluChon), or saline, since 7 days prior to surgery until the sacrifice 70 days after ACLT. A positive control group received meloxicam 6 mg/kg s.c. for antinociceptive evaluation comparisons. Joint pain was evaluated with rat incapacitation test. Animals were sacrificed 7,14,28 or 70 days after ACLT. The severity of histopathologic lesions was evaluated on femoral condyles after hematoxylin-eosin or toluidine blue staining with OARSI grading and staging system. Cartilage extracted glycosaminoglycans (GAGs) concentration was assessed after agarose gel electrophoresis. GAGs\' molecular weight was evaluated after polyacrylamide gel electrophoresis. NO release in synovial fluids was assessed 7 days after ACLT. RESULTS: GluChon reduced joint pain (p<0.01). Glu also reduced joint pain, but results did not reach statistical significance. A significant increase in articular cartilage\'s GAGs concentration was observed in OA animals (77.68±3.38 µg/mg) as compared to sham (53.46±4.58 µg/mg). OA animals also had significantly higher molecular weight GAGs than sham (p<0.01). GluChon prevented both GAG concentration and molecular weight elevations in OA animals, and that was associated with significant less cartilage damage assessed by histopathologic examination (p<0.05). Glu effects were less evident, and did not reach statistical significance. Glu was associated with significant higher concentrations of NO in synovial fluid. CONCLUSIONS: GluChon was antinociceptive on the ACLT model in rats. Articular cartilage damage was associated with increased amounts of GAG with higher molecular weight, and the prevention of these alterations with GluChon treatment was associated with less histopathologic damage. GluChon was more efficient than Glu for both pain and articular cartilage damage reduction, suggesting that combined treatment is better than glucosamine sulfate alone.